Dorian Therapeutics
acquired by Altos LabsYC S18San Francisco, US · Founded 2018 · 8 employees · 2 known investors
Dorian Therapeutics was a biotechnology startup developing senoblockers, drugs designed to rejuvenate cells and tissues by targeting aging-related mechanisms. Acquired by Altos Labs.
Founders & leadership· Y Combinator alumni (S18)
Dorian Therapeutics was founded in 2018 by Maddalena Adorno and Benedetta di Robilant.
Investors · 2
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $452.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $335.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Dorian Therapeutics do?
- Dorian Therapeutics was a biotechnology startup developing senoblockers, drugs designed to rejuvenate cells and tissues by targeting aging-related mechanisms. Acquired by Altos Labs.
- Who founded Dorian Therapeutics?
- Dorian Therapeutics was founded by Maddalena Adorno, Benedetta di Robilant in 2018.
- Who are Dorian Therapeutics's investors?
- Dorian Therapeutics's investors include Blumberg Capital, Y Combinator.
- Who acquired Dorian Therapeutics?
- Dorian Therapeutics was acquired by Altos Labs.
- Where is Dorian Therapeutics headquartered?
- Dorian Therapeutics is headquartered in San Francisco, US.